Talk:Tianeptine

message: The Ki values given are higher than codeine i.e. VERY WEAK. IF it has a strong opioid affect, it's a metabolite. I have seen an opioid with 2 aromatics with a dimethylamine on the bridging carbon. I seem to remember one of the organics being a pyridine and I THINK it had a m-OH on the benzene. Doxpicomine & Ciramadol both have 1 methylene between aromatics. There is analogue of ciramadol with a p-Cl in place of the m-OH. The Os of the -SO2-, like the N may have lone-pair interaction. Well, I will leave it with Chemoffice installed to overlay them. I would also be interested in the O to N to aromatic (so 2 choices - the further away one) and see how it matches nortilidine. The 7-membered ring will place the N further.  — Preceding unsigned comment added by 213.106.56.145 (talk) 14:08, 14 December 2015 (UTC)
thread_title: Opioid Affinity

message: tianeptine has never undergone the gold standard i.e. testing against a tricyclic  antidepressant compared against placebo. Why not,I do not know. I cannot believe that it has not been done as the first publication about tianeptine date from 1989  This site seems very close to the talk of pharmaceutic representative of Ardix. One should ask why this fantastic substance has not been approved by the FDA.
:Um, because the patent that Servier has on tianeptine has expired? Fortunately, Vela Pharmaceuticals (acquired recently by Pharmos) is interested. Yes,  I know it's an...interesting website, but they're the only ones who've explained why Sevier hasn't tried marketing it in the US, besides the fact that so many people here have grown up on the idea that depression is merely a serotonin defiency. This is probably why Pharmos is marketing it for irritable bowel syndrome.--Rmky87 21:08, 8 July 2006 (UTC)
thread_title: Placebo

message: Is someone going to fix this at some point? The conspicuous lack of chlorine anywhere in the image should have clued in anyone who actually looks at it.
When someone finally does attempt to fix it, please note:
http://www.biopsychiatry.com/tianeptine/tianeptine.jpg
This image is also wrong. Count the carbons.
http://www.genome.jp/dbget-bin/www_bget?dr+D02575
This image is correct.
--76.209.58.121 14:34, 27 February 2007 (UTC)
replies: text: Fixed, thank you for noticing. Fvasconcellos 16:56, 27 February 2007 (UTC)
thread_title:  The molecular image is still wrong. 

message: Anyone skilled/knowledgeable enough to search and document how and why Tianeptine hasn't been submited/approved in USA/Canada ?
Marty (whereismarty@hotmail.com)
69.70.202.20 (talk) 20:39, 2 June 2008 (UTC)
replies: text: "It is not marketed in North America because its patent has expired. To gain a US product license, a raft of costly new clinical trials would be needed by the FDA. Unfortunately, American regulators are habitually sceptical of the calibre of European medical science." That source is of unknown quality. Since it is at tianeptine.com it could be profit motivated. 71.86.152.127 (talk) 17:46, 27 September 2009 (UTC)
replies: text: It has also been said (I don't remember the source) that American and European drug companies tend to "respect each other's turf", that is, they don't try to push medicines on each other continents, in part because both of them are assumed (correctly IMO) to be favored by the regulatory bodies in their respective regions, so that a European drug will have a harder time getting approved when there is an American drug for the same condition and vice versa (so that often it doesn't make economic sense even to try to get things approved on the other side of the Atlantic). Historian932 (talk) 03:26, 21 June 2011 (UTC)
thread_title:  History of Tianeptine: Rejection in America 

message: The 3D formula ist wrong since only one of the two enantiomers is shown. Tianeptine is a racemate. Best regards, --Jü (talk) 17:45, 25 July 2012 (UTC)
replies: text: It's not really wrong to show a single stereoisomer.  Any chemist capable of understanding the depiction will recognize that it is possible to show only a single enantiomer in a single representation and it would be pointless to use two.  ChemNerd (talk) 19:53, 6 August 2012 (UTC)
thread_title:  3D formula 

message: Hello everybody,
I placed a merge from tag in the Tianeptine article, because the article selective serotonin reuptake enhancer (SSRE) is about nothing else than tianeptine, and in addition, it's whole justification comes from an outdated theory (that tianeptine's antidepressant effect comes from enhanced serotonin reuptake). I suggest to copy what's worth to include in the tianeptine article, and afterwards replace the content of SSRE by a forward to tianeptine. The redundancy of both articles is a maintenance obstacle.
Best, --Richard (talk) 18:14, 2 March 2014 (UTC)
replies: text: I wouldn't call the theory outdated, per se, I realise there are other actions that have recently come to light but still it hasn't been proven that this isn't a contributing factor; but I do agree with you I think the two should be merged. Plus tianeptine isn't truly a selective serotonin reuptake enhancer, it also enhances norepinephrine's reuptake. (PMID: 15361747) Fuse809 (talk) 11:44, 6 March 2014 (UTC)
replies: text:  Do you have access to the full article with PMID 15361747? If so, please share which are the 4th and 5th cite in this article, because I found no source for a norepinephrine reuptake enhancing mechanism of Tianeptine. The term monoamine reuptake enhancer can't be justified just by the title of a paper. Sheldon Preskorn is a MD, who doesn't do this research on his own. Best --Richard (talk) 10:13, 11 March 2014 (UTC)
replies: text:  I do and the good point, the two sources he cites do not mention effects on norepinephrine reuptake. Fuse809 (talk) 11:18, 11 March 2014 (UTC)
replies: text:  Thx, but when they don't mention effects on norepinephrine reuptake, then the 1st sentence in Tianeptine#Mechanism of action should be edited again. --Richard (talk) 21:12, 11 March 2014 (UTC)

text: I'd suggest keeping the pages apart and simply note that the theory is outdated on the SSRE page.  This page should evolve without the baggage of the, now empty, SSRE class of drugs. Seppi333 (Insert 2¢ | Maintained) 16:09, 6 March 2014 (UTC)
replies: text:  It's not meaningful to keep an article stub which only mentions that some medication was once thougt to be the only class member. A new SSRE article could easily be written, if an SSRE would be developed. One could redirect SSRE to a stub serotonine reuptake enhancer (SRE), whith Tianeptine as the only class member (and without the redundancy to Tianeptine). But even if Tianeptine has SRE property isn't sure (PMC 2902200), as it is not known/scientifically debated if Tianeptine really enhances serotonin reuptake or even decreases the serotonin-level for longer as the beginning of a treatment (an effect that occours also frequently in SSRI). So I'm still thinking it's best to forward to Tianeptine, where already is written, that it was called a Serotonin Reuptake Enhancer. Best --Richard (talk) 10:13, 11 March 2014 (UTC)
thread_title:  Merging article SSRE into Tianeptine 

message: We have a seemingly contradictory statements in the article: on the one hand, the lead paragraph mentions "a relative lack of sedative, anticholinergic and cardiovascular adverse effects"; the reference in the section 'Side effects' states that the proarrhythmogenic effects of tianeptine have not been well studied. Should we rectify the lead? --Eleassar my talk 10:13, 13 February 2016 (UTC)
thread_title: CVS effects

message: I added a caveat that tianeptine is more than safe to use concurrently with MAOIs because there is no pharmacological contraindication. Tianeptine lacks any serotonergic/noradrenergic activity that would make this combination unsafe. If you would like to challenge me, please go ahead because there are no actual reports of an unsafe interaction transpiring with MAOIs; there is so much misinformation regarding MAOIs permeating psychiatry it's mind boggling, it's no better than sheer hysteria. 
47.184.211.178 (talk) 20:24, 11 March 2019 (UTC)
thread_title:  Tianeptine in combination w/ MAOIs 

message: In the section listing tianeptine's affinity at various targets, the table is labelled Ki. Ki refers to inhibition and is clearly not applicable when describing an agonist (such as at MOR Kd should be used). Unfortunately this error seems to be prevalent across wikipedia.
Wdhiwhfwaih (talk) 01:47, 14 March 2021 (UTC)
thread_title:  Use of incorrect pharmacodynamic terms